These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27798418)

  • 1. T2-low asthma: current approach to diagnosis and therapy.
    Samitas K; Zervas E; Gaga M
    Curr Opin Pulm Med; 2017 Jan; 23(1):48-55. PubMed ID: 27798418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of asthma endotypes: implications for therapy.
    Stokes JR; Casale TB
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.
    Dunican EM; Fahy JV
    Ann Am Thorac Soc; 2015 Nov; 12 Suppl 2(Suppl 2):S144-9. PubMed ID: 26595730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginsenoside Rh2 attenuates allergic airway inflammation by modulating nuclear factor-κB activation in a murine model of asthma.
    Li LC; Piao HM; Zheng MY; Lin ZH; Choi YH; Yan GH
    Mol Med Rep; 2015 Nov; 12(5):6946-54. PubMed ID: 26502836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum IL-17A and Th2 cytokine levels in patients with severe uncontrolled asthma.
    Hasegawa T; Uga H; Mori A; Kurata H
    Eur Cytokine Netw; 2017 Mar; 28(1):8-18. PubMed ID: 28840844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological treatments for severe asthma: A major advance in asthma care.
    Busse WW
    Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different endotypes and phenotypes drive the heterogeneity in severe asthma.
    McDowell PJ; Heaney LG
    Allergy; 2020 Feb; 75(2):302-310. PubMed ID: 31267562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharides promote a shift from Th2-derived airway eosinophilic inflammation to Th17-derived neutrophilic inflammation in an ovalbumin-sensitized murine asthma model.
    Zhao S; Jiang Y; Yang X; Guo D; Wang Y; Wang J; Wang R; Wang C
    J Asthma; 2017 Jun; 54(5):447-455. PubMed ID: 27589490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient stratification and the unmet need in asthma.
    Swedin L; Saarne T; Rehnberg M; Glader P; Niedzielska M; Johansson G; Hazon P; Catley MC
    Pharmacol Ther; 2017 Jan; 169():13-34. PubMed ID: 27373855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inflammatory cytokines (IL-4, IL-5 and IL-13)].
    Maeda S; Yanagihara Y
    Nihon Rinsho; 2001 Oct; 59(10):1894-9. PubMed ID: 11676128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?
    Parulekar AD; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2017 Jan; 23(1):3-11. PubMed ID: 27820746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of biologics in asthma endotypes.
    Wangberg H; Woessner K
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of T2 inflammation biomarkers in severe asthma.
    Parulekar AD; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2016 Jan; 22(1):59-68. PubMed ID: 26574724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
    Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
    Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice.
    Mizutani N; Nabe T; Yoshino S
    J Immunol; 2014 Feb; 192(4):1372-84. PubMed ID: 24446518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
    Matera MG; Rogliani P; Calzetta L; Cazzola M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.
    Moss RB
    Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursolic acid, a potential PPARγ agonist, suppresses ovalbumin-induced airway inflammation and Penh by down-regulating IL-5, IL-13, and IL-17 in a mouse model of allergic asthma.
    Kim SH; Hong JH; Lee YC
    Eur J Pharmacol; 2013 Feb; 701(1-3):131-43. PubMed ID: 23201068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.